Baird Downgrades Cepheid to Neutral

Brokerage firm Baird Downgrades its rating on Cepheid(NASDAQ:CPHD). The shares have been rated Neutral. Previously, the analysts had a Outperform rating on the shares. The rating by Baird was issued on Sep 12, 2016.

In a different note, On Sep 8, 2016, Citigroup said it Downgrades its rating on Cepheid. In the research note, the firm Raises the price-target to $44.00 per share. The shares have been rated ‘Neutral’ by the firm. On Sep 7, 2016, Cowen & Company said it Downgrades its rating on Cepheid. The shares have been rated ‘Market Perform’ by the firm. On Sep 7, 2016, Barclays said it Maintains its rating on Cepheid. In the research note, the firm Raises the price-target to $36.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Sep 7, 2016, BTIG Research said it Downgrades its rating on Cepheid. The shares have been rated ‘Neutral’ by the firm. On Sep 7, 2016, Baird said it Maintains its rating on Cepheid. In the research note, the firm Raises the price-target to $44.00 per share. The shares have been rated ‘Outperform’ by the firm. On Sep 6, 2016, PiperJaffray said it Downgrades its rating on Cepheid. The shares have been rated ‘Neutral’ by the firm.

Cepheid (CPHD) shares turned negative on Tuesdays trading session with the shares closing down -0.07 points or -0.13% at a volume of 22,88,512. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $52.625. The peak price level was also seen at $52.625 while the days lowest was $52.44. Finally the shares closed at $52.49. The 52-week high of the shares is $53.91 while the 52-week low is $25.09. According to the latest information available, the market cap of the company is $3,832 M.

Cepheid(CPHD) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $146.00M. Analysts had an estimated revenue of $145.94M. Earnings per share were $0.05.

Several Insider Transactions has been reported to the SEC. On Aug 17, 2016, Scott A. Campbell (Corporate VP & CRO) sold 287 shares at $36.16 per share price.Also, On May 3, 2016, Peter V. Farrell (EVP, Worldwide Commercial Ops) sold 390 shares at $28.90 per share price.On Apr 27, 2016, John L Bishop (Chairman of the Board and CEO) sold 110,000 shares at $35.50 per share price, according to the Form-4 filing with the securities and exchange commission.

Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Cepheid - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cepheid. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.